Skip to main content
Top
Published in: Annals of Nuclear Medicine 7/2021

01-07-2021 | Original Article

Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors

Authors: Yuya Sekikawa, Keita Funada, Go Akamatsu, Kazuhiko Himuro, Akihiko Takahashi, Shingo Baba, Masayuki Sasaki

Published in: Annals of Nuclear Medicine | Issue 7/2021

Login to get access

Abstract

Objective

To examine the impact of acquisition time on Lutetium-177 (177Lu) single-photon emission computed tomography (SPECT) images using Monte Carlo simulation.

Methods

A gamma camera simulation based on the Monte Carlo method was performed to produce SPECT images. The phantom was modeled on a NEMA IEC BODY phantom including six spheres as tumors. After the administration of 7.4 GBq of 177Lu, radioactivity concentrations of the tumor/liver at 6, 24, and 72 h after administration were set to 1.85/0.201, 2.12/0.156, and 1.95/0.117 MBq/mL, respectively. In addition, the radioactivity concentrations of the tumor at 72 h after administration varied by 1/2, 1/4, and 1/8 when comparison was made. Acquisition times examined were 1.2, 1.5, 2, 3, 6, and 12 min. To assess the impact of collimators, SPECT data acquired at 72 h after the administration using six collimators of low-energy high-resolution (LEHR), extended low-energy general-purpose (ELEGP), medium-energy, and general-purpose (MEGP-1, MEGP-2, and MEGP-3) and high-energy general-purpose (HEGP) were examined. After prefiltering using a Butterworth filter, projection images were reconstructed using ordered subset expectation maximization. The detected photons were classified into direct rays, scattered rays, penetrating rays, and characteristic X-rays from lead. The image quality was evaluated through visual assessment, and physical assessment of contrast recovery coefficient (CRC) and contrast-to-noise ratio (CNR). In this study, the CNR threshold for detectability was assumed to be 5.0.

Results

To compare collimators, the highest sensitivity was observed with ELEGP, followed by LEHR and MEGP-1. The highest ratio of direct ray was also observed in ELEGP followed by MEGP-1. In comparison of the radioactivity concentration ratios of tumor/liver, CRC and CNR were significantly decreased with smaller radioactivity concentration ratios. This effect was greater with larger spheres. According to the visual assessment, the acquisition time of 6, 6, and 3 min or longer was required using ELEGP collimator at 6, 24, and 72 h after administration, respectively. Physical assessment based on CNR and CRC also suggested that 6, 6, and 3 min or longer acquisition time was necessary at 6, 24, and 72 h after administration.

Conclusion

177Lu-SPECT images generated via the Monte Carlo simulation suggested that the recommended acquisition time was 6 min or longer at 6 and 24 h and 3 min or longer at 72 h after administration.
Literature
1.
go back to reference Kellett MA. 177Lu: DDEP Assessment of the decay scheme for an emerging radiopharmaceutical. Appl Radiat Isot. 2016;109:129–32.CrossRef Kellett MA. 177Lu: DDEP Assessment of the decay scheme for an emerging radiopharmaceutical. Appl Radiat Isot. 2016;109:129–32.CrossRef
2.
go back to reference Kossert K, Näle OJ, Ott O, Dersch R. Activity determination and nuclear decay data of 177Lu. Appl Radiat Isot. 2012;70:2215–21.CrossRef Kossert K, Näle OJ, Ott O, Dersch R. Activity determination and nuclear decay data of 177Lu. Appl Radiat Isot. 2012;70:2215–21.CrossRef
3.
go back to reference Sanders JC, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT/CT imaging of 177Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17:585–93.CrossRef Sanders JC, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT/CT imaging of 177Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17:585–93.CrossRef
4.
go back to reference Gleisner KS, Brolin G, Sundlöv A, Mjekiqi E, Östlund K, Tennvall J, et al. Long-Term retention of 177Lu/177mLu-DOTATATE in patients investigated by g-spectrometry and g-camera imaging. J Nucl Med. 2016;56:976–84.CrossRef Gleisner KS, Brolin G, Sundlöv A, Mjekiqi E, Östlund K, Tennvall J, et al. Long-Term retention of 177Lu/177mLu-DOTATATE in patients investigated by g-spectrometry and g-camera imaging. J Nucl Med. 2016;56:976–84.CrossRef
6.
go back to reference Satapathy S, Mittal B. 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun. 2019;40(12):1195–203.CrossRef Satapathy S, Mittal B. 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun. 2019;40(12):1195–203.CrossRef
7.
go back to reference Garkavij M, Nickel M, Gleisner KS, Ljungberg M, Ohlsson T, Wingårdh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRef Garkavij M, Nickel M, Gleisner KS, Ljungberg M, Ohlsson T, Wingårdh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRef
9.
go back to reference Melis M, Swart JD, Visser MD, Berndsen SC, Koelewijin S, Valkema R, et al. Dynamic and static small-animal spect in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy. J Nucl Med. 2010;51:1962–68.CrossRef Melis M, Swart JD, Visser MD, Berndsen SC, Koelewijin S, Valkema R, et al. Dynamic and static small-animal spect in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy. J Nucl Med. 2010;51:1962–68.CrossRef
12.
go back to reference Chicheportiche A, Haim SB, Glasberg SG, Oleinikov K, Meirovitz A, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. Eur J Nucl Med Mol Imaging. 2020;7:5. https://doi.org/10.1186/s40658-020-0273-8.CrossRef Chicheportiche A, Haim SB, Glasberg SG, Oleinikov K, Meirovitz A, et al. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. Eur J Nucl Med Mol Imaging. 2020;7:5. https://​doi.​org/​10.​1186/​s40658-020-0273-8.CrossRef
13.
go back to reference Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Gross DJ, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate specific membrane antigen. J Nucl Med. 2005;46:850–58.PubMed Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Gross DJ, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate specific membrane antigen. J Nucl Med. 2005;46:850–58.PubMed
14.
go back to reference Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRef Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRef
15.
go back to reference Hijnen NM, Vries AD, Nicolay K, Grüll H. Dual-isotope 111In/177Lu SPECT imaging as a tool in molecular imaging tracer design. Contrast Media Mol Imaging. 2012;7:214–22.CrossRef Hijnen NM, Vries AD, Nicolay K, Grüll H. Dual-isotope 111In/177Lu SPECT imaging as a tool in molecular imaging tracer design. Contrast Media Mol Imaging. 2012;7:214–22.CrossRef
16.
go back to reference Meyer JV, Magill S, Lee J, Umetsu S, Flavell R. Detection of Metastatic Meningioma to the Liver Using 68Ga-DOTA-Octreotate PET/CT. Clin Nucl Med. 2018;43(9):338–40.CrossRef Meyer JV, Magill S, Lee J, Umetsu S, Flavell R. Detection of Metastatic Meningioma to the Liver Using 68Ga-DOTA-Octreotate PET/CT. Clin Nucl Med. 2018;43(9):338–40.CrossRef
17.
go back to reference Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66.CrossRef Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66.CrossRef
20.
go back to reference Shcherbinin S, Bilska HP, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/90Y targeted radionuclide therapies. Phys Med Biol. 2012;57:5733–47.CrossRef Shcherbinin S, Bilska HP, Celler A, Birkenfeld B. Quantitative SPECT/CT reconstruction for 177Lu and 177Lu/90Y targeted radionuclide therapies. Phys Med Biol. 2012;57:5733–47.CrossRef
21.
go back to reference D’Arienzo M, Cazzato M, Cozzella ML, Cox M, D’Andra M, Fazio A, et al. Gamma camera calibration and validation for quantitative SPECT imaging with 177Lu. Appl Radiation and Isotopes. 2016;112:156–64.CrossRef D’Arienzo M, Cazzato M, Cozzella ML, Cox M, D’Andra M, Fazio A, et al. Gamma camera calibration and validation for quantitative SPECT imaging with 177Lu. Appl Radiation and Isotopes. 2016;112:156–64.CrossRef
22.
go back to reference Uehara S. The development of a Monte Carlo code simulating electron-photon showers and its assessment by various transport benchmarks. Nucl Insrum Methods Phys Res B. 1986;14:559–70.CrossRef Uehara S. The development of a Monte Carlo code simulating electron-photon showers and its assessment by various transport benchmarks. Nucl Insrum Methods Phys Res B. 1986;14:559–70.CrossRef
23.
go back to reference Takahashi A, Himuro K, Yamashita Y, Komiya I, Baba S, Sasaki M. Monte Carlo simulation of PET and SPECT imaging of 90Y. Med Phys. 2015;42(4):1926–35.CrossRef Takahashi A, Himuro K, Yamashita Y, Komiya I, Baba S, Sasaki M. Monte Carlo simulation of PET and SPECT imaging of 90Y. Med Phys. 2015;42(4):1926–35.CrossRef
24.
go back to reference Tanaka M, Uehara S, Kojima A, Matsumoto M. Monte Carlo simulation of energy spectra for 123I imaging. Phys Med Biol. 2007;52:4409–25.CrossRef Tanaka M, Uehara S, Kojima A, Matsumoto M. Monte Carlo simulation of energy spectra for 123I imaging. Phys Med Biol. 2007;52:4409–25.CrossRef
25.
go back to reference Takahashi A, Miwa K, Sasaki M, Baba S. A Monte Carlo study on 223Ra imaging for unsealed radionuclide therapy. Med Phys. 2016;43(6):2965–74.CrossRef Takahashi A, Miwa K, Sasaki M, Baba S. A Monte Carlo study on 223Ra imaging for unsealed radionuclide therapy. Med Phys. 2016;43(6):2965–74.CrossRef
26.
go back to reference Kälkner KM, Janson ET, Nilsson S, Carlsson S, Öberg K, Westrin JE, et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res. 1995;55:5801–4. Kälkner KM, Janson ET, Nilsson S, Carlsson S, Öberg K, Westrin JE, et al. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res. 1995;55:5801–4.
28.
go back to reference Brolin G, Gustafsson J, Ljungberg M, Gleisner KS. Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in 177Lu-DOTATATE peptide receptor radionuclide therapy. Phys Med Biol. 2015;60:6131–49.CrossRef Brolin G, Gustafsson J, Ljungberg M, Gleisner KS. Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in 177Lu-DOTATATE peptide receptor radionuclide therapy. Phys Med Biol. 2015;60:6131–49.CrossRef
29.
go back to reference Taniguchi T, Akamatsu G, Kasahara Y, Mitsumoto K, Baba S, Tsutsui Y, et al. Improvement in PET/CT image quality in overweight patients with PSF and TOF. Ann Nucl Med. 2015;29:71–77.CrossRef Taniguchi T, Akamatsu G, Kasahara Y, Mitsumoto K, Baba S, Tsutsui Y, et al. Improvement in PET/CT image quality in overweight patients with PSF and TOF. Ann Nucl Med. 2015;29:71–77.CrossRef
30.
go back to reference Hashimoto N, Morita K, Tsutsui Y, Himuro K, Baba S, Sasaki M. Time-of-flight information improved the detectability of subcentimeter spheres using a clinical PET/CT scanner. J Nucl Med Technol. 2018;46(3):268–73.CrossRef Hashimoto N, Morita K, Tsutsui Y, Himuro K, Baba S, Sasaki M. Time-of-flight information improved the detectability of subcentimeter spheres using a clinical PET/CT scanner. J Nucl Med Technol. 2018;46(3):268–73.CrossRef
31.
go back to reference Rose A. Vision: human and electronic. Optical physics and engineering. New York: Plenum Press; 1973. Rose A. Vision: human and electronic. Optical physics and engineering. ​New York: Plenum Press; 1973.
32.
go back to reference Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Pennsylvania: Elsevier; 2003. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd ed. Pennsylvania: Elsevier; 2003.
33.
go back to reference de Nijsa R, Lagerburg V, Klausena TL, Holm S. Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections. Nucl Med Commun. 2014;35:522–33.CrossRef de Nijsa R, Lagerburg V, Klausena TL, Holm S. Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections. Nucl Med Commun. 2014;35:522–33.CrossRef
34.
go back to reference Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD Pamphlet No 26: Joint EANM/MIRD guidelines for quantitative 177Lu SPECT. Applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57:151–62.CrossRef Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD Pamphlet No 26: Joint EANM/MIRD guidelines for quantitative 177Lu SPECT. Applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57:151–62.CrossRef
35.
go back to reference Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy. Acta Oncol. 2012;51:86–96.CrossRef Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, et al. Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy. Acta Oncol. 2012;51:86–96.CrossRef
36.
37.
go back to reference Bai B, Esser PD. The effect of edge artifacts on quantification of positron emission tomography. In: IEEE nuclear science symposium and medical imaging conference (NSS/MIC). 2010. p. 2263–66. Bai B, Esser PD. The effect of edge artifacts on quantification of positron emission tomography. In: IEEE nuclear science symposium and medical imaging conference (NSS/MIC). 2010. p. 2263–66.
38.
go back to reference Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative 177Lu SPECT/CT with xSPECT quant. J Nucl Med. 2019;60:50–9.CrossRef Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative 177Lu SPECT/CT with xSPECT quant. J Nucl Med. 2019;60:50–9.CrossRef
39.
go back to reference Daou D, Pointurier I, Coaguila C, Vilain D, Benada AW, Lebtahi R, et al. Performance of OSEM and depth-dependent resolution recovery algorithms for the evaluation of global left ventricular function in 201Tl gated myocardial perfusion SPECT. J Nucl Med. 2003;44:155–62.PubMed Daou D, Pointurier I, Coaguila C, Vilain D, Benada AW, Lebtahi R, et al. Performance of OSEM and depth-dependent resolution recovery algorithms for the evaluation of global left ventricular function in 201Tl gated myocardial perfusion SPECT. J Nucl Med. 2003;44:155–62.PubMed
40.
go back to reference Kidera D, Kihara K, Akamatsu G, Mikasa S, Taniguchi T, Tsutsui Y, et al. The edge artifact in the point-spread function-based PET reconstruction at different sphere-to-background ratios of radioactivity. Ann Nucl Med. 2016;30:97–103.CrossRef Kidera D, Kihara K, Akamatsu G, Mikasa S, Taniguchi T, Tsutsui Y, et al. The edge artifact in the point-spread function-based PET reconstruction at different sphere-to-background ratios of radioactivity. Ann Nucl Med.  2016;30:97–103.CrossRef
Metadata
Title
Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors
Authors
Yuya Sekikawa
Keita Funada
Go Akamatsu
Kazuhiko Himuro
Akihiko Takahashi
Shingo Baba
Masayuki Sasaki
Publication date
01-07-2021
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 7/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-021-01620-9

Other articles of this Issue 7/2021

Annals of Nuclear Medicine 7/2021 Go to the issue